Expanding Its Radiopharmaceutical Footprint
Sofie Biosciences is a US-based contract manufacturing organisation focused on radiopharmaceuticals used in positron emission tomography (PET) imaging. It operates a network of 15 manufacturing sites and 21 cyclotrons across the US, offering GE HealthCare enhanced capacity to manufacture and distribute time-sensitive PET products.
The acquisition is poised to bolster GE HealthCare's Pharmaceutical Diagnostics business, with a wider presence across the radiopharmaceutical supply chain.
Building a 'Final Mile' Supply Network
Radiopharmaceuticals demand highly specialised manufacturing and logistics due to the short radioactive half-lives of many products. F18-labeled PET products, for example, have a half-life of approximately 110 minutes, requiring timely manufacturing and delivery.
Sofie's network could support GE HealthCare in addressing the critical "final mile" between radiopharmaceutical production and healthcare providers. The company anticipates the acquisition could improve supply reliability and patient access to PET imaging products.
FAPI-74 Adds to GE HealthCare's Cancer Imaging Pipeline
The transaction will also grant GE HealthCare US rights to FAPI-74, a Phase III PET radiotracer under development for imaging fibroblast activation protein across multiple cancer types. GE HealthCare already possesses rights to the product outside the US.
With successful development and approval, FAPI-74 could expand the company's portfolio of precision-imaging products and deepen its footprint in an area where diagnostics are increasingly being integrated with targeted therapies.
A Larger Bet on Precision Medicine
The acquisition aligns with radiopharmaceuticals' growing role in precision medicine, where molecular imaging is coupled with the potential for targeted treatment. GE HealthCare believes the deal will enable it to participate across more segments of the radiopharmaceutical value chain, from manufacturing and imaging technology to digital workflows and radiotherapeutics infrastructure.
The deal is expected to close in the first half of 2027, subject to regulatory approvals and other conditions. GE HealthCare forecasts the acquisition will positively impact revenue growth, adjusted EBIT margin, and adjusted EPS in the first full year of ownership.
The $945 million deal thus represents more than an expansion of GE HealthCare's manufacturing capacity: it reflects a larger strategy to seize the growth in radiopharmaceuticals, precision diagnostics, and theranostics as healthcare turns to more targeted and data-driven approaches to disease detection and treatment.